Anal Intraepithelial Neoplasia
13
1
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
31%
4 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (13)
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
COrSIcA: Disease Measurement
Anal Cancer Risk In Women
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
Function Following Laser for Anal Intraepithelial Neoplasia (FLAN)
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia
Biomarkers to Detect Anal Intraepithelial Neoplasia in Thai Men Who Have Sex With Men
Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men